[1] Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, Halliday GM, Bartus RT (2013) Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease. Brain 136, 2419-2431.
[2] Park SB, Kwon KY, Lee JY, Im K, Sunwoo JS, Lee KB, Roh H, Ahn MY, Park S, Kim SJ, Oh JS, Kim JS (2019) Lack of association between dopamine transporter loss and non-motor symptoms in patients with Parkinson’s disease: a detailed PET analysis of 12 striatal subregions. Neurol Sci 40, 311-317.
[3] Yousaf T, Pagano G, Niccolini F, Politis M (2018) Exces- sive daytime sleepiness may be associated with caudate denervation in Parkinson disease. J Neurol Sci 387, 220- 227.
[4] Klingelhoefer L, Reichmann H (2015) Pathogenesis of Parkinson disease–the gut-brain axis and environmental fac- tors. Nat Rev Neurol 11, 625-636.
[5] Berg D, Marek K, Ross GW, Poewe W (2012) Defining at-risk populations for Parkinson’s disease: lessons from ongoing studies. Mov Disord 27, 656-665.
[6] Krismer F, Wenning GK (2017) Multiple system atrophy: insights into a rare and debilitating movement disorder. Nat Rev Neurol 13, 232-243.
[7] Watanabe H, Saito Y, Terao S, Ando T, Kachi T, Mukai E, Aiba I, Abe Y, Tamakoshi A, Doyu M, Hirayama M, Sobue G (2002) Progression and prognosis in multiple sys- tem atrophy: an analysis of 230 Japanese patients. Brain 125, 1070–1083.
[8] Wenning GK, Geser F, Krismer F, Seppi K, Duerr S, Boesch S, Ko¨llensperger M, Goebel G, Pfeiffer KP, Barone P, Pel- lecchia MT, Quinn NP, Koukouni V, Fowler CJ, Schrag A, Mathias CJ, Giladi N, Gurevich T, Dupont E, Ostergaard K, Nilsson CF, Widner H, Oertel W, Eggert KM, Albanese A, Del Sorbo F, Tolosa E, Cardozo A, Deuschl G, Hellriegel H, Klockgether T, Dodel R, Sampaio C, Coelho M, Djaldetti R, Melamed E, Gasser T, Kamm C, Meco G, Colosimo C, Rascol O, Meissner WG, Tison F, Poewe W; European Multiple System Atrophy Study Group (2013) The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 12, 264-274.
[9] Low PA, Reich SG, Jankovic J, Shults CW, Stern MB, Novak P, Tanner CM, Gilman S, Marshall FJ, Wooten F, Racette B, Chelimsky T, Singer W, Sletten DM, Sandroni P, Mandrekar J (2015) Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol 14, 710- 719.
[10] Watts JC, Giles K, Oehler A, Middleton L, Dexter DT, Gentleman SM, DeArmond SJ, Prusiner SB (2013) Trans- mission of multiple system atrophy prions to transgenic mice. Proc Natl Acad SciUSA 110, 19555-19560.
[11] Prusiner SB, Woerman AL, Mordes DA, Watts JC, Ramper- saud R, Berry DB, Patel S, Oehler A, Lowe JK, Kravitz SN, Geschwind DH, Glidden DV, Halliday GM, Middleton LT, Gentleman SM, Grinberg LT, Giles K (2015) Evidence for alpha-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc Natl Acad SciUSA 112, E5308-5317.
[12] Kraemmer K, Kovacs GG, Perju-Dumbrava L, Pirker S, Traub-Weidinger T, Pirker W (2014) Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts. Mov Disord 29, 1767-1773.
[13] Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Colosimo C, Du¨rr A, Fowler CJ, Kaufmann H, Klockgether T, Lees A, Poewe W, Quinn N, Revesz T, Robertson D, Sandroni P, Seppi K, Vidailhet M (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71, 670-676.
[14] Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinic-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55, 181-184.
[15] Mizumura S, Nishikawa K, Murata A, Yoshimura K, Ishii N, Kokubo T, Morooka M, Kajiyama A, Terahara A (2018) Improvement in the measurement error of the specific bind- ing ratio in dopamine transporter SPECT imaging due to exclusion of the cerebrospinal fluid fraction using the thresh- old of voxel RI count. Ann Nucl Med 32, 288-296.
[16] Yamamoto H, Arimura S, Nakanishi A, Shimo Y, Motoi Y, Ishiguro K, Murakami K, Hattori N, Aoki S (2017) Age- related effects and gender differences in Japanese healthy controls for [123I] FP-CIT SPECT. Ann Nucl Med 31, 407- 412.
[17] Tossici-Bolt L, Hoffmann SM, Kemp PM, Mehta RL, Flem- ing JS (2006) Quantification of [123I]FP-CIT SPECT brain images: an accurate technique for measurement of the specific binding ratio. Eur J Nucl Med Mol Imaging 33, 1491-1499.
[18] Dickson JC, Tossici-Bolt L, Sera T, Erlandsson K, Varrone A, Tatsch K, Hutton BF (2010) The impact of reconstruction method on the quantification of DaTSCAN images. Eur J Nucl Med Mol Imaging 37, 23-35.
[19] Tison F, Yekhlef F, Chrysostome V, Balestre E, Quinn NP, Poewe W, Wenning GK (2002) Parkinsonism in multiple system atrophy: natural history, severity (UPDRS-III), and disability assessment compared with Parkinson’s disease. Mov Disord 17, 701-709.
[20] Nocker M, Seppi K, Donnemiller E, Virgolini I, Wenning GK, Poewe W, Scherfler C (2012) Progression of dopamine transporter decline in patients with the Parkinson vari- ant of multiple system atrophy: a voxel-based analysis of [123I]beta-CIT SPECT. Eur J Nucl Med Mol Imaging 39, 1012-1020.
[21] Varrone A, Marek KL, Jennings D, Innis RB, Seibyl JP (2001) [123I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkin- son’s disease and multiple system atrophy. Mov Disord 16, 1023-1032.
[22] Knudsen GM, Karlsborg M, Thomsen G, Krabbe K, Regeur L, Nygaard T, Videbaek C, Werdelin L (2004) Imaging of dopamine transporters and D2 receptors in patients with Parkinson’s disease and multiple system atrophy. Eur J Nucl Med Mol Imaging 31, 1631-1638
[23] Scherfler C, Seppi K, Donnemiller E, Goebel G, Brenneis C, Vigolini I, Wenning GK, Poewe W (2005) Voxel-wise anal- ysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkin- son’s disease. Brain 128, 1605-1612.
[24] Antonini A, Benti R, De Notaris R, Tesei S, Zacchinelli A, Sacilotto G, Meucci N, Canesi M, Mariani C, Pezzoli G, Gerundini P (2003) 123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson’s disease, multiple system atrophy, and progres- sive supranuclear palsy. Neurol Sci 24, 149-150.
[25] Lyoo CH, Jeong Y, Ryu YH, Lee SY, Song TJ, Lee JH, Rinne JO, Lee MS (2008) Effects of disease duration on the clinical features and brain glucose metabolism in patients with mixed type multiple system atrophy. Brain 131, 438- 446.
[26] Ozawa T, Paviour D, Quinn NP, Josephs KA, Sangha H, Kil- ford L, Healy DG, Wood NW, Lees AJ, Holton JL, Revesz T (2004) The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain 127, 2657-2671.
[27] Pirker W, Djamshidian S, Asenbaum S, Gerschlager W, Tribl G, Hoffmann M, Bru¨cke T (2002) Progression of dopaminergic degeneration in Parkinson’s disease and atyp- ical parkinsonism: a longitudinal beta-CIT SPECT study. Mov Disord 17, 45-53.
[28] Bru¨cke T, Djamshidian S, Bencsits G, Pirker W, Asen- baum S, Podreka I (2000) SPECT and PET imaging of the dopaminergic system in Parkinson’s disease. J Neurol 247 (Suppl 4), IV/2-7.